Antoniazzi Franco

1
CURRICULUM della ATTIVITÀ SCIENTIFICA E DIDATTICA
Prof. Franco Antoniazzi
Nato a Legnago (VR) il 22-2-1959.
Laurea in Medicina e Chirurgia presso l'Università degli Studi di Bologna il 21-10-1983, Anno
Accademico 1982-83, con votazione di 110/110 con lode.
Specializzazione in Pediatria presso l'Università degli Studi di Verona il 16-7-1987, Anno Accademico
1986-87, con votazione di 70/70 con lode.
Dal 1-12-1986 al 16-11-1987 stage presso l'Unité de Genetique Medicale - INSERM U 12 di Parigi,
diretta dal Prof. Pierre Maroteaux, con attività clinica e di ricerca nel campo delle osteocondrodisplasie
dell'infanzia e della Osteogenesi Imperfetta in particolare.
Dottore di Ricerca in "Fisiopatologia Metabolica Congenita" il 13-4-1992.
Dal 1-11-1989 al 30-4-1994 Assistente Medico a tempo pieno nella disciplina di Pediatria presso
l'ULSS 25 Regione Veneto. Dal 1-5-1994 al 31-10-1995 in servizio come Aiuto Corresponsabile
Ospedaliero presso il Servizio Autonomo di Endocrinologia Pediatrica, ULSS 25 Regione Veneto. Dal
1-11-1995 al 31-10-2006 in servizio come Aiuto Corresponsabile Ospedaliero (ora Dirigente Medico di
I livello) presso la Clinica Pediatrica dell'Università di Verona, Azienda Ospedaliera di Verona.
Dal 1-3-1995 al 30-6-1995 stage presso l'Hôpital Saint Vincent de Paul di Parigi, Pediatria C,
Endocrinologia e Diabetologia Pediatrica, di Parigi, diretta dal Prof. J.L. Chaussain.
Specializzazione in Endocrinologia e Malattie del Ricambio presso l'Università degli Studi di Verona il
15-3-2001, Anno Accademico 1999-2000, con votazione di 48/50.
Professore a Contratto presso le Scuole di Specializzazione di Pediatria, di Otorinolaringoiatria e di
Chirurgia Pediatrica dell’Università di Verona.
Membro dal 1993 al 1996 del Comitato Scientifico Internazionale per la Osteogenesi Imperfetta; dal 4
giugno 2002 membro dell European Medical Advisory Board of Osteogenesis Imperfecta Federation
Europe.
Membro della European Society for Paediatric Endocrinology (ESPE) dall’anno 1995 a tuttora.
Idoneità a Professore Associato nella disciplina MED-38 Pediatria generale e specialistica, conseguita
il 5 dicembre 2005 presso l’università di Bologna.
Professore Associato nella disciplina MED-38 Pediatria Generale e Specialistica presso l’Università di
Verona dal 1 novembre 2006. Confermato in ruolo come Professore Associato a decorrere dal 1
novembre 2009.
Responsabile della Struttura Semplice Funzionale di Endocrinologia e Metabolismo presso la Clinica
Pediatrica di Verona dal 11 agosto 2008.
Partecipazione a numerosi Lavori Scientifici, a Congressi come Relatore, soprattutto nel campo della
endocrinologia pediatrica e dei problemi scheletrici dell'infanzia.
Verona 20 novembre 2012
Prof. Franco ANTONIAZZI
2
3
Campi di ricerca e Pubblicazioni principali

Ricerca di mutazioni nella Osteogenesi Imperfetta:
o
Valli M, Mottes M, Tenni R, Sangalli A, Gomez Lira M, Rossi A, Antoniazzi F, Cetta G, Pignatti
PF. A de novo G to T transversion in a pro-alpha 1 (I) collagen gene for a moderate case of
osteogenesis imperfecta. Substitution of cysteine for glycine 178 in the triple helical domain. J
Biol Chem. 1991 Jan 25;266(3):1872-8.
o
Valli M, Zolezzi F, Mottes M, Antoniazzi F, Stanzial F, Tenni R, Pignatti P, Cetta G. Gly85 to Val
substitution in pro alpha 1(I) chain causes mild osteogenesis imperfecta and introduces a
susceptibility to protease digestion. Eur J Biochem. 1993 Oct 1;217(1):77-82.
o
Mottes M, Sangalli A, Valli M, Forlino A, Gomez-Lira M, Antoniazzi F, Constantinou-Deltas CD,
Cetta G, Pignatti PF. A base substitution at IVS-19 3'-end splice junction causes exon 20
skipping in pro alpha 2(I) collagen mRNA and produces mild osteogenesis imperfecta. Hum
Genet. 1994 Jun;93(6):681-7.
o
Venturi G, Tedeschi E, Mottes M, Valli M, Camilot M, Viglio S, Antoniazzi F, Tato L.
Osteogenesis imperfecta: clinical, biochemical and molecular findings. Clin Genet. 2006
Aug;70(2):131-9.
o
Tedeschi E, Antoniazzi F, Venturi G, Zamboni G, Tato L. Osteogenesis imperfecta and its
molecular diagnosis by determination of mutations of type I collagen genes. Pediatr Endocrinol
Rev. 2006 Sep;4(1):40-6.
o
Valli M, Barnes AM, Gallanti A, Cabral WA, Viglio S, Weis M, Makareeva E, Eyre D, Leikin S,
Antoniazzi F, Marini JC, Mottes M. Deficiency of CRTAP in Non-lethal Recessive Osteogenesis
Imperfecta Reduces Collagen Deposition into Matrix. Clin Genet. 2011 Sep 28. doi:
10.1111/j.1399-0004.2011.01794.x. [Epub ahead of print]
o
Venturi G, Monti E, Carbonare LD, Corradi M, Gandini A, Valenti MT, Boner A, Antoniazzi F. A
novel splicing mutation in FKBP10 causing osteogenesis imperfecta with a possible
mineralization defect. Bone. 2011 Oct 30. [Epub ahead of print] PubMed PMID: 22061863.
o
Venturi G, Gandini A, Monti E, Dalle Carbonare L, Corradi M, Vincenzi M, Valenti MT, Valli M,
Pelilli E, Boner A, Mottes M, Antoniazzi F. Lack of expression of SERPINF1, the gene coding for
pigment epithelium-derived factor causes progressively deforming osteogenesis imperfecta with
normal type I collagen. J Bone Miner Res. 2011 Nov 23. doi: 10.1002/jbmr.1480. [Epub ahead of
print] PubMed PMID: 22113968.

Trattamento della Osteogenesi Imperfetta:
o
Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, Zamboni G, Valentini R, Tato L. Growth
hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen
synthesis. J Pediatr. 1996 Sep;129(3):432-9.
o
Antoniazzi F, Mottes M, Fraschini P, Brunelli PC, Tato L. Osteogenesis imperfecta: practical
treatment guidelines. Paediatr Drugs. 2000 Nov-Dec;2(6):465-88. Review.
4
o
Gatti D, Colapietro F, Fracassi E, Sartori E, Antoniazzi F, Braga V, Rossini M, Adami S. The
volumetric bone density and cortical thickness in adult patients affected by osteogenesis
imperfecta. J Clin Densitom. 2003 Summer;6(2):173-7.
o
Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adami S. Intravenous
neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone
Miner Res. 2005 May;20(5):758-63. Epub 2004 Dec 20.
o
Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tatò L. Early bisphosphonate treatment
in infants with severe osteogenesis imperfecta. J Pediatrics 2006; 149: 174-9.
o
Rugolotto S, Monti E, Carli M, Pietrobelli A, Antoniazzi F, Tato L. Pulmonary function tests in an
infant with osteogenesis imperfecta and early biphosphonate treatment. Acta Paediatr. 2007
Dec;96(12):1856-1857.
o
Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P,
Antoniazzi F. Current and emerging treatments for the management of osteogenesis imperfecta.
Ther Clin Risk Manag. 2010 Sep 7;6:367-81. PubMed PMID: 20856683; PubMed Central
PMCID: PMC2940745.
o
Antoniazzi F, Monti E, Venturi G, Franceschi R, Doro F, Gatti D, Zamboni G, Tatò L. GH in
combination with bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol. 2010
Sep;163(3):479-87. Epub 2010 Jun 30. PubMed PMID: 20592128.
o
Maines E, Monti E, Doro F, Morandi G, Cavarzere P, Antoniazzi F. Children and adolescents
treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of
the jaw. J Bone Miner Metab. 2011 Nov 8. [Epub ahead of print] PubMed PMID: 22065238.

Osteocondrodisplasie:
o
Colamaria V, Mazza C, Beltramello A, Polo A, Boner A, Antoniazzi F, Polo M, Luchini P, Sgro V,
Dalla Bernardina B. Irreversible respiratory failure in an achondroplastic child: the importance of
an early cervicomedullary decompression, and a review of the literature. Brain Dev. 1991
Jul;13(4):270-9.
o
Unger S, Antoniazzi F, Brugnara M, Alanay Y, Caglayan A, Lachlan K, Ikegawa S, Nishimura G,
Zabel B, Spranger J, Superti-Furga A. 2008. Clinical and radiographic delineation of
odontochondrodysplasia. Am J Med Genet Part A. 2008 mar 15; 146A (6):770-8

Disordini della Pubertà: Pubertà Precoce.
o
Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F, De Sanctis C, Rigon F,
Zamboni G, Bernasconi S, et al. Final height in girls with central precocious puberty: comparison
of two different luteinizing hormone-releasing hormone agonist treatments. Acta Paediatr. 1994
Oct;83(10):1052-6.
o
Tato L, Saggese G, Cavallo L, Antoniazzi F, Corrias A, Pasquino AM, Cisternino M. Use of
combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty
5
treatment. Horm Res. 1995;44 Suppl 3:49-54.
o
Antoniazzi F, Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Borrelli P, Osio D,
Mengarda F, De Luca F, Tato L. End results in central precocious puberty with GnRH analog
treatment: the data of the Italian Study Group for Physiopathology of Puberty. J Pediatr
Endocrinol Metab. 2000 Jul;13 Suppl 1:773-80.
o
Tato L, Savage MO, Antoniazzi F, Buzi F, Di Maio S, Oostdijk W, Pasquino AM, Raiola G,
Saenger P, Tonini G, Voorhoeve PG; International Workshop on Management of Puberty for
Optimum Auxological Results. Optimal therapy of pubertal disorders in precocious/early puberty.
J Pediatr Endocrinol Metab. 2001 Jul;14 Suppl 2:985-95.
o
Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, Messina MF, Lombardo F.
Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with
idiopathic precocious puberty. Eur J Endocrinol. 2004 Apr;150(4):533-7.
o
Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs.
2004;6(4):211-31. Review.
o
Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Iughetti L, Pasquino AM, Salerno MC, Marseglia L,
Crisafulli G. Menstrual cycle pattern during the first gynaecological years in girls with precocious
puberty following gonadotropin-releasing hormone analogue treatment. Eur J Pediatr. 2007; 166
(1):73-4.
o
Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR; ESPE-LWPES GnRH Analogs
Consensus Conference Group, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP,
Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P,
Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman
D, Styne D, Tauber M, Wit JM. Consensus statement on the use of gonadotropin-releasing
hormone analogs in children. Pediatrics. 2009 Apr;123(4):e752-62. Epub 2009 Mar 30.
o
Franceschi R, Gaudino R, Marcolongo A, Gallo MC, Rossi L, Antoniazzi F, Tatò L. Prevalence of
polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil
Steril. 2010 Mar 1;93(4):1185-91
o
Cavarzere P, Vincenzi M, Gaudino R, Franceschi R, Perlini S, Camilot M, Teofoli F, Antoniazzi
F, Tatò L. Possible andrologic markers in elevated neonatal 17-hydroxyprogesterone. Fertil
Steril. 2010 Nov;94(6):2350-2. Epub 2010 May 26. PubMed PMID: 20537623.
o
Predieri B, Luisi S, Casarosa E, Farinelli E, Antoniazzi F, Wasniewska M, Bernasconi S,
Petraglia F, Iughetti L; Italian Society Pediatric Endocrinology - Study Group of Puberty.
Allopregnanolone Levels Decrease after Gonadotropin Releasing Hormone Analogue
Stimulation Test in Girls with Central Precocious Puberty. J Endocrinol Invest. 2011; 34: 38-44.

Disordini della Pubertà: Pubertà Ritardata e Ipogonadismo
o
Zamboni G, Antoniazzi F, Tato L. Use of the gonadotropin-releasing hormone agonist triptorelin
in the diagnosis of delayed puberty in boys. J Pediatr. 1995 May;126(5 Pt 1):756-8.
6
o
Tato L, Zamboni G, Antoniazzi F, Piubello G. Gonadal function and response to growth hormone
(GH) in boys with isolated GH deficiency and to GH and gonadotropins in boys with multiple
pituitary hormone deficiencies. Fertil Steril. 1996 Apr;65(4):830-4.

Ipertiroidismo
o
Antoniazzi F, Zamboni G, Cerini R, Lauriola S, Dall'Agnola A, Tato L. Graves' ophthalmopathy
evolution studied by MRI during childhood and adolescence. J Pediatr. 2004 Apr;144(4):527-31.

Ipotiroidismo Congenito
o
Franceschi R, Cavarzere P, Gaudino R, Monti E, Perlini S, Vanzati M, Camilot M, Teofoli F,
Antoniazzi F, Lauriola S, Albertini C, Tatò L. [Influence of thyroid morphology on psychomotor
development in patients with congenital hypothyroidism during 8 year follow-up.]. Minerva
Pediatr. 2010 Jun;62(3):253-260. Italian. PubMed PMID: 20467377.

Studio dei Fattori di crescita
o
Zamboni G, Dufillot D, Antoniazzi F, Valentini R, Gendrel D, Tato L. Growth hormone-binding
proteins and insulin-like growth factor-binding proteins in protein-energy malnutrition, before and
after nutritional rehabilitation. Pediatr Res. 1996 Mar;39(3):410-4.
o
Radetti G, Paganini C, Antoniazzi F, Pasquino B, Valentini R, Gentili L, Tato L. Growth hormonebinding proteins, IGF-I and IGF-binding proteins in children and adolescents with type 1 diabetes
mellitus. Horm Res. 1997;47(3):110-5.
o
Zamboni G, Antoniazzi F, Tato L. Insulin-like growth factor binding protein-3 proteolysis and
growth of athyreotic infants in the first weeks of life. Acta Paediatr. 2000 Sep;89(9):1050-5.
o
Zaffanello M, Malerba G, Cataldi L, Antoniazzi F, Franchini M, Monti E, Fanos V. Genetic risk for
recurrent urinary tract infections in humans: a systematic review. J Biomed Biotechnol.
2010;2010:321082. Epub 2010 Mar 30. PubMed PMID: 20379347; PubMed Central PMCID:
PMC2847765.

Studio del metabolismo osseo
o
Zamboni G, Antoniazzi F, Spolettini E, Tato L. Mineral metabolism in obese children after weight
loss. Acta Paediatr Scand. 1991 Apr;80(4):470-1.
o
Zamboni G, Antoniazzi F, Radetti G, Musumeci C, Tato L. Effects of two different regimens of
recombinant human growth hormone therapy on the bone mineral density of patients with growth
hormone deficiency. J Pediatr. 1991 Sep;119(3):483-5.
o
Antoniazzi F, Radetti G, Zamboni G, Gambaro G, Adami S, Tato L. Effects of 1,25dihydroxyvitamin D3 and growth hormone therapy on serum osteocalcin levels in children with
growth hormone deficiency. Bone Miner. 1993 May;21(2):151-6.
o
Antoniazzi F, Bertoldo F, Zamboni G, Valentini R, Sirpresi S, Cavallo L, Adami S, Tato L. Bone
7
mineral metabolism in girls with precocious puberty during gonadotropin-releasing hormone
agonist treatment. Eur J Endocrinol. 1995 Oct;133(4):412-7.
o
Antoniazzi F, Bertoldo F, Lauriola S, Sirpresi S, Gasperi E, Zamboni G, Tato L. Prevention of
bone demineralization by calcium supplementation in precocious puberty during gonadotropinreleasing hormone agonist treatment. J Clin Endocrinol Metab. 1999 Jun;84(6):1992-6.
o
Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, Tato L. Bone mass
at final height in precocious puberty after gonadotropin-releasing hormone agonist with and
without calcium supplementation. J Clin Endocrinol Metab. 2003 Mar;88(3):1096-101.
o
Zamboni G, Antoniazzi F, Bertoldo F, Lauriola S, Antozzi L, Tato L. Altered bone metabolism in
children infected with human immunodeficiency virus. Acta Paediatr. 2003;92(1):12-6.
o
Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Tato L. Bone development during GH and
GnRH analog treatment. Eur J Endocrinol. 2004 Aug;151 Suppl 1:S47-54. Review.
o
Zamboni G, Antoniazzi F, Lauriola S, Bertoldo F, Tato L. Calcium Supplementation Increases
Bone Mass in GH-Deficient Prepubertal Children during GH Replacement. Horm Res. 2006 Mar
28;65(5):223-230
o
Franco Antoniazzi, Elena Monti, Rossella Gaudino, Paolo Cavarzere, Marco Zaffanello, Milena
Brugnara, Silvia Perlini, Evelina Maines, Maria Chiara Gallo, Sara Dal Corso, Dario Zanon,
Luciano Tatò. Bone density in children treated with gonadotropin-releasing hormone analogs for
central precocious puberty. Expert Rev. Endocrinol. Metab. 5(2), 285–290 (2010).